Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli

Article Abstract:

The facile isolation of full-length antibodies from combinatorial libraries expressed in Escherichia coli is described. Full-length heavy and light chains are secreted into the periplasm, where they assemble into aglycosylated IgGs and after permeabilizing the outer membrane, spheroplast clones expressing E-clonal antibodies which recognize fluorescently labeled antigen are selected using flow cytometry.

Health aspects, Usage, Physiological aspects, Escherichia coli, Flow cytometry, Immunoglobulin G

---

Avimers hold their own

Article Abstract:

Stemmer and coworkers came out with a new class of antibody surrogates that have high ligand affinity, low immunogenicity and the capacity for high expression in bacteria. Their approach generated proteins that have the requisite binding affinity, are sufficiently small to ensure rapid systemic distribution after subcutaneous administration and show prolonged persistence in circulation.

Protein research, Binding proteins

---

Enzyme beauty

Article Abstract:

At the fifteenth Enzyme Engineering Conference, current research was presented (and discussed in this article) which caused the authors of this article to wonder what new developments in genetics are in store, including molecular breeding.

Research and Development in the Physical, Engineering, and Life Sciences, Genetic Engineering

Similar abstracts:

• Abstracts: Selecting and screening recombinant antibody libraries. Production of human monoclonal antibody in eggs of chimeric chickens
• Abstracts: An investigation of regulatory and voluntary environmental capital expenditures. Mandatory environmental disclosures in a legitimacy theory context
• Abstracts: Polyclonal antibodies step out of the shadows. Supreme Court boosts licensees in biotech patent battles. GlaxoSmithKline cancer drug threatens Herceptin market
• Abstracts: Serono changes tack. Antibiotics au naturel
• Abstracts: Tuft's report backs FDA fast-track, but post-marketing concerns loom

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.